argenx logo

argenx

Biotechnology

Boston, Massachusetts, United States
1,000-5,000 employees
Founded 2008

argenx is a global immunology biotechnology company that develops antibody-based medicines for severe autoimmune diseases. Its lead commercial product is VYVGART (efgartigimod), an FcRn blocker approved for generalized myasthenia gravis and related indications.

  • VYVGART (efgartigimod) - FcRn blocker for generalized myasthenia gravis
  • VYVGART Hytrulo - for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Empasiprubart (pipeline) - anti-C2 antibody for IgM-driven autoimmune diseases

Open roles at argenx

89 matching roles

Showing 12 of 89 roles